Alnylam Pharmaceuticals, Inc. (ALNY)

NASDAQ: ALNY · Real-Time Price · USD

458.12

-7.22 (-1.55%)

At close: Dec 5, 2025, 4:00 PM EST

451.16

-6.96 (-1.52%)

After-hours: Dec 5, 2025, 7:40 PM EST

-1.55% (1D)

Market Cap	60.52B
Revenue (ttm)	3.21B
Net Income (ttm)	43.57M
Shares Out	132.11M
EPS (ttm)	0.33
PE Ratio	1,388.85
Forward PE	69.54
Dividend	n/a
Ex-Dividend Date	n/a

Volume	627,337
Open	468.29
Previous Close	465.34
Day's Range	455.32 - 473.50
52-Week Range	205.87 - 495.55
Beta	0.30
Analysts	Strong Buy
Price Target	483.89 (+5.63%)
Earnings Date	Oct 30, 2025

About ALNY

Alnylam Pharmaceuticals, Inc. discovers, develops, and commercializes therapeutics based on ribonucleic acid interference. It offers ONPATTRO and AMVUTTRA for hereditary transthyretin-mediated amyloidosis; GIVLAARI for acute hepatic porphyria; OXLUMO for primary hyperoxaluria type 1; and Leqvio for hypercholesterolemia. It also develops vutrisiran, which is in phase III clinical trial for transthyretin amyloidosis (ATTR) with cardiomyopathy; Nucresiran that is in phase I clinical trial for ATTR amyloidosis; Fitusiran, which is in phase III clin... [Read more]

Industry Biotechnology

Sector Healthcare

IPO Date May 28, 2004

Employees 2,230

Stock Exchange NASDAQ

Ticker Symbol ALNY

Website https://www.alnylam.com

Full Company Profile

Financial Performance

In 2024, Alnylam Pharmaceuticals's revenue was $2.25 billion, an increase of 22.97% compared to the previous year's $1.83 billion. Losses were -$278.16 million, -36.82% less than in 2023.

Financial Statements

Analyst Forecast

According to 27 analysts, the average rating for ALNY stock is "Strong Buy." The 12-month stock price target is $483.89, which is an increase of 5.63% from the latest price.

Price Target

$483.89

(5.63% upside)

Analyst Consensus: Strong Buy

Stock Forecasts

News

Alnylam Pharmaceuticals Announces Changes to Board of Directors

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced changes to its Board of Directors, including the departure of tw...

2 days ago - Business Wire

CRH, Vertiv, Ares, Alnylam Could Be Added to S&P 500 Friday in Rebalancing

Those four companies, culled from a list drawn up by KBW analyst Shreyank Gandhi, are among the largest not in the index.

Other symbols: CRH VRT ARCC

4 days ago - Barrons

American Century Ultra Fund Q3 2025 Contributors/Detractors And Notable Trades

Google's parent company received a relatively benign antitrust ruling that would not force Alphabet to sell its Chrome browser or Android operating system. Chipotle Mexican Grill reported mixed quarte...

Other symbols: CMG FICO GOOG LULU MSFT NFLX ORCL

5 days ago - Seeking Alpha

What's Going On With Alnylam Stock On Friday?

Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) stock is trading higher on Friday, with no news to justify the movement.

7 days ago - Benzinga

Virtus Silvant Mid-Cap Growth Fund Q3 2025 Performance Review

The Virtus Silvant Mid-Cap Growth Fund returned +5.43% (Class INST) for the quarter, compared to the Russell Midcap Growth Index's return of +2.78%. Palantir Technologies (PLTR) and Roblox (RBLX) were...

Other symbols: AFRM AJG ALAB AXON DXCM FICO HOOD

9 days ago - Seeking Alpha

UK's drug-cost watchdog recommends Alnylam's heart disease drug

The UK's drug cost-effectiveness watchdog has recommended Alnylam Pharmaceuticals' heart disease drug, ensuring access for patients through the government health system in England and Wales, the compa...

15 days ago - Reuters

Alnylam Pharmaceuticals, Inc. (ALNY) Presents at Jefferies London Healthcare Conference 2025 Transcript

Alnylam Pharmaceuticals, Inc. ( ALNY) Jefferies London Healthcare Conference 2025 November 19, 2025 6:30 AM EST Company Participants Yvonne Greenstreet - CEO & Director Tolga Tanguler - Executive VP ...

16 days ago - Seeking Alpha

Got $5,000? 3 Top Growth Stocks to Buy That Could Double Your Money

Alnylam Pharmaceuticals boasts an exciting product lineup and pipeline. IonQ could be one of the biggest winners in the fast-growing quantum computing market.

Other symbols: IONQ TOST

24 days ago - The Motley Fool

Alnylam Pharmaceuticals, Inc. (ALNY) Presents at UBS Global Healthcare Conference 2025 Transcript

Alnylam Pharmaceuticals, Inc. ( ALNY) UBS Global Healthcare Conference 2025 November 10, 2025 10:15 AM EST Company Participants Jeffrey Poulton - CFO & Executive VP John Vest - Senior Vice President ...

25 days ago - Seeking Alpha

New Post Hoc Analysis from the HELIOS-B Phase 3 Study Shows Vutrisiran Improved Measures of Heart Structure and Function in Patients with ATTR-CM

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced results from new post hoc analyses of the HELIOS-B Phase 3 study...

27 days ago - Business Wire

American Century Focused Dynamic Growth Fund Q3 2025 Performance Contributors And Detractors

Google's parent company received a relatively benign antitrust ruling that would not force Alphabet to sell its Chrome browser or Android operating system. Alnylam's shares benefited from a positive p...

Other symbols: AAPL APP CMG GOOGL INSM NFLX STZ

4 weeks ago - Seeking Alpha

Alnylam to Webcast Presentations at Upcoming November Investor Conferences

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that management will present company overviews at the following ...

4 weeks ago - Business Wire

Biotech is back. Here's why these rallying stocks belong in your portfolio now.

The volatile sector is seeing greater stability, and these four stocks can profit.

Other symbols: ABBV AMGN BMY LLY MBX MDGL MEDI

4 weeks ago - Market Watch

Alnylam Pharmaceuticals: Q3 Earnings Review - A Sensational Year Reaches Its Peak

Alnylam Pharmaceuticals, Inc. delivered strong Q3 results, driven by Amvuttra's success in ATTR-CM, with total revenues soaring to $1.25 billion. ALNY's market cap surged to $59B as Amvuttra outperfor...

5 weeks ago - Seeking Alpha

Alnylam Pharmaceuticals, Inc. (ALNY) Q3 2025 Earnings Call Transcript

Alnylam Pharmaceuticals, Inc. ( ALNY) Q3 2025 Earnings Call October 30, 2025 8:30 AM EDT Company Participants Christine Lindenboom - Chief Corporate Communications Officer Yvonne Greenstreet - CEO & ...

5 weeks ago - Seeking Alpha

Why Is Alnylam Pharmaceuticals Stock Trading Lower Thursday?

Alnylam Pharmaceuticals Inc. (NASDAQ:ALNY) stock is trading lower after the company reported third-quarter earnings.

5 weeks ago - Benzinga

Alnylam Pharmaceuticals Reports Third Quarter 2025 Financial Results and Highlights Recent Period Progress

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today reported its consolidated financial results for the third quarter ended Se...

5 weeks ago - Business Wire

Alnylam to Webcast Conference Call Discussing Third Quarter 2025 Financial Results

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that it will report financial results for the third quarter endi...

7 weeks ago - Business Wire

Alnylam Announces First Patient Dosed in ZENITH Global Phase 3 Cardiovascular Outcomes Trial of Zilebesiran

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced that the first patient has been dosed in ZENITH (ZilebEsiraN Car...

2 months ago - Business Wire

New Data from HELIOS-B Phase 3 Study Demonstrate Lower Rates of Gastrointestinal Events in ATTR-CM Patients Treated with Vutrisiran

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced results from new analyses of the HELIOS-B Phase 3 study of AMVUT...